Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis

Autor: Drellia, K. Kokoti, L. Deligianni, C.I. Papadopoulos, D. Mitsikostas, D.D.

Introduction and objective: Monoclonal antibodies targeting the calcitonin gene-related peptide pathway (anti-CGRP mAbs) have shown promising efficacy in randomised clinical trials for the prevention of episodic and chronic migraine, but no head-to-h

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::7875d43e6d88a6bd0a0a6c42dbe37b1a
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3119667

Disease-modifying treatments for multiple sclerosis have not affected the incidence of neoplasms in clinical trials over 3 decades: a meta-analysis with meta-regression.

Autor: Papadopoulos D; School of Medicine, European University Cyprus, Nicosia, 2404, Cyprus. d.papadopoulos@otenet.gr.; Salpetriere Neuropsychiatric Clinic, Metamorphosi, 14452, Greece. d.papadopoulos@otenet.gr., Gklinos P; Department of Neurology, KAT General Hospital of Attica, Athens, 14561, Greece., Psarros G; ASTAT- Statistics in Clinical Research, Athens, 16675, Greece., Drellia K; Department of Neurology, Korgialenio-Benakio 'Hellenic Red Cross' General Hospital, Athens, 11526, Greece., Delicha EM; ASTAT- Statistics in Clinical Research, Athens, 16675, Greece., Friede T; Department of Medical Statistics, University Medical Center Göttingen, Göttingen, Germany., Mitsikostas DD; 1St Neurology Department, Aeginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, 11528, Greece., Nicholas RS; Department of Cellular and Molecular Neuroscience, Imperial College London, London, W12 0NN, UK.; UCL Institute of Ophthalmology, London, EC1V 9RL, UK.; Population Data Science, Swansea University Medical School, Swansea, SA2 8PP, UK.

Publikováno v: Journal of neurology [J Neurol] 2022 Jun; Vol. 269 (6), pp. 3226-3237. Date of Electronic Publication: 2022 Jan 23.

Risk of cancer development associated with disease-modifying therapies for multiple sclerosis: study protocol for a systematic review and meta-analysis of randomised and non-randomised studies.

Autor: Catalá-López, Ferrán^1,2,3 (AUTHOR) ferran_catala@outlook.com, Tejedor-Romero, Laura⁴ (AUTHOR), Driver, Jane A.^5,6,7 (AUTHOR), Hutton, Brian^3,8 (AUTHOR), Sánchez-Ortí, Joan Vicent^2,9 (AUTHOR), Ridao, Manuel^10,11,12 (AUTHOR), Alonso-Arroyo, Adolfo^13,14 (AUTHOR), Correa-Ghisays, Patricia^2,9 (AUTHOR), Forés-Martos, Jaume^2,15 (AUTHOR), Balanzá-Martínez, Vicent^2,9 (AUTHOR), Valencia, Alfonso^16,17 (AUTHOR), Cobos, Inmaculada¹⁵ (AUTHOR), Tabarés-Seisdedos, Rafael^2,9 (AUTHOR) rafael.tabares@uv.es

Publikováno v: Systematic Reviews. 10/18/2024, Vol. 13 Issue 1, p1-8. 8p.

Guidelines of the International Headache Society for controlled trials of pharmacological preventive treatment for persistent post-traumatic headache attributed to mild traumatic brain injury.

Autor: Ashina, Håkan^1,2,3,4,5 (AUTHOR) hashina@bidmc.harvard.edu, Diener, Hans-Christoph⁶ (AUTHOR), Tassorelli, Cristina^7,8 (AUTHOR), Scher, Ann I.⁹ (AUTHOR), Lipton, Richard B.^10,11 (AUTHOR), Pozo-Rosich, Patricia^12,13 (AUTHOR), Sinclair, Alexandra J.¹⁴ (AUTHOR), Chong, Catherine D.¹⁵ (AUTHOR), Finkel, Alan G.¹⁶ (AUTHOR), Ashina, Messoud^3,5 (AUTHOR), Schwedt, Todd J.¹⁵ (AUTHOR), Dodick, David W.^5,15 (AUTHOR), Terwindt, Gisela M.¹⁷ (AUTHOR)

Publikováno v: Cephalalgia. Mar2024, Vol. 44 Issue 3, p1-18. 18p.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.